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A preparative regimen of reduced intensity that can reliably engraft cord blood (CB) and can be used as an
alternative to either high-dose myeloablative or nonmyeloablative conditioning is needed. We evaluated
double-unit CB transplantation in 30 patients (median age, 56 years; range, 18 to 69) with acute leukemia or
myelodysplasia using a regimen of cyclophosphamide 50 mg/kg, ﬂudarabine 150 mg/m2, thiotepa 10 mg/kg,
and 400 cGy total body irradiation with cyclosporine-A/mycophenolate mofetil immunosuppression. Ninety-
seven percent of patients engrafted at a median of 26 days (range, 13 to 43), and 93% of patients had
recovered platelets by day 180. Grades II to IV acute graft-versus-host disease (GVHD) incidence was 67% at
day 180, and chronic GVHD was 10% at 1 year. Transplant-related mortality was 20% at day 180, and relapse
was 11% at 2 years. Overall, 2-year disease-free survival (DFS) was 60% at 2 years. A hierarchy in DFS was seen
according to the Sorror comorbidity score: 11 patients (median age, 55 years) with a score of 1 had a 2-year
DFS of 82% compared with 62% in 9 patients (median age, 51 years) with a score of 2 to 3 and 40% in
11 patients (median age, 58 years) with a score of 4 to 5 (P ¼ .13). This reduced-intensity regimen combined
with double-unit CB transplantation reliably facilitates sustained donor engraftment without antithymocyte
globulin. Although other approaches are needed in patients with high comorbidity scores, this regimen is
highly effective in patients 50 years old who are otherwise reasonably ﬁt. It also represents a promising
alternative to high-dose conditioning in younger patients.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION To address these limitations, we investigated the safety
Double-unit cord blood transplantation (CBT) has been
effective at reducing transplant-related mortality (TRM)
compared with single-unit CBT historical control subjects
[1]. Improvement in high-dose myeloablative double-unit
CBT is needed, however, due to the risk of lethal regimen-
related organ toxicity [2]. Nonmyeloablative (NMA) and
reduced-intensity conditioning have been investigated as
strategies to reduce TRM and extend transplant access to
older patients or those with signiﬁcant comorbidities [3-6].
However, NMA conditioning is limited by the combined risks
of graft rejection in patients without extensive prior chem-
otherapy [3] and relapse [7-9]. Although rejection may
be reduced by adding antithymocyte globulin (ATG), this
in vivo T cell depletion increases the risk of viral infections
and Epstein-Barr virus lymphoproliferative disease [10,11]
and has been associated with increased TRM [4]. ATG could
also increase relapse risk [12,13].dgments on page 802.
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13.02.007and efﬁcacy of a novel ATG-free reduced-intensity regimen.
We used the cyclophosphamide, ﬂudarabine, total body
irradiation (TBI) 200 cGy NMA platform originally reported
by the University of Minnesota [3,4], but we intensiﬁed the
regimen by adding thiotepa and increasing the TBI dose to
400 cGy. In addition, to augment engraftment and possibly
the antileukemia potential [14-17], we used double-unit
grafts in all patients. We investigated this double-unit
CBT approach as an alternative to either high-dose myeloa-
blative or NMA conditioning in adult patients with the
hypothesis that it would induce a high incidence of sustained
donor engraftment without ATG and have a low incidence
of relapse.
METHODS
Patients Characteristics
Patients underwent transplantation atMemorial Sloan-Kettering Cancer
Center between October 1, 2007 and August 30, 2011, and provided
informed consent for transplantation and outcome analysis in accordance
with the Declaration of Helsinki. The trial is registered on ClinicalTrials.gov
(NCT00739141). We report in this analysis all consecutive patients age 18 to
69 years who ﬁrst received hematopoietic stem cell transplants and with
diagnoses of acute myelogenous or lymphoblastic leukemia in complete
morphologic remission (CR1 to CR3) or myelodysplasia with5% blasts. The
indication for this reduced-intensity regimen was a diagnosis of acuteTransplantation.
Table 1
Patient (n ¼ 30) and Graft Characteristics (60 units)
Characteristics Value
Median age, yr (range) 56 (18-69)
Male, n (%) 15 (50)
Median weight, kg (range) 69 (48-103)
Recipient CMV seropositive, n (%) 21 (70)
Diagnosis/disease status,* n (%)
AML 21 (70)
CR1 16
3 poor risk cytogeneticsy
5 FLT3-ITD mutation
6 secondary to therapy or prior MDS/MPD
2 with 3 inductions
CR2 5
ALL 5 (17)
CR1 4
3 Philadelphia chromosome-positive
1 refractory CNS disease that cleared before
allograft
CR3 1
MDS 4 (13)
CR1 1
Stable disease 1
Hematologic improvement 2
Disease risk, n (%)
Standard 1 (3)
High 29 (97)
Donorerecipient HLA-match, n (%)
6/6 4 (7)
5/6 32 (53)
4/6 24 (40)
Median infused TNC  107/kg (range)
Larger unit 2.6 (1.5-5.6)
Smaller unit 1.9 (1.4-2.5)
Median infused CD34þ  105/kg (range)
Larger unit .9 (.4-3.3)
Smaller unit .5 (.2-1.5)
CMV indicates cytomegalovirus; AML, acute myelogenous leukemia; ALL,
acute lymphoblastic leukemia; MPD, myeloproliferative disease; TNC, total
nucleated cell.
* Two patients had multiple hematologic malignancies: 1 with AML and
chronic lymphocytic leukemia and 1 with MDS and non-Hodgkin
lymphoma.
y Included monosomy 7 (n ¼ 1), 11q23 translocation (n ¼ 1), and del 5q
(n ¼ 1).
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factors of age 50 years, and/or extensive prior therapy, and/or signiﬁcant
comorbidities, making the patient ineligible or inappropriate for high-dose
myeloablative conditioning. Standard-risk disease for acute leukemia
was deﬁned as CR1 without high-risk cytogenetics/high-risk molecular
abnormalities or de novo myelodysplasia with an International Prognostic
Scoring System score <2. All remaining patients were considered high
risk [2]. The hematopoietic cell transplant comorbidity index (HCT-CI) score
of Sorror et al. [18] was retrospectively assigned for the purposes of
this analysis.
Conditioning Regimen, Graft-versus-Host Disease Prophylaxis, and
Graft Characteristics
Conditioning consisted of cyclophosphamide 50 mg/kg (day 6), ﬂu-
darabine 30 mg/m2/day for 5 (days 6 to 2), thiotepa 5 mg/kg/day for
2 (days 5 and 4), and TBI 200 cGy/day for 2 (days 2 and 1) (Cy 50/Flu
150/Thio 10/TBI 400). If the recipient was greater than 125% of ideal body
weight, the doses of cyclophosphamide, ﬂudarabine, and thiotepa were
calculated on adjusted body weight.
Cyclosporine A and mycophenolate mofetil were used as graft-versus-
host disease (GVHD) prophylaxis starting on day 3 intravenously. Cyclo-
sporine A was dosed to achieve a trough level of 200 to 400 ng/mL.
Mycophenolate mofetil was given in a dose of 1 g every 12 hours for the ﬁrst
17 patients and was increased to 1 g every 8 hours for the subsequent
13 patients to augment GVHD prophylaxis [19].
Double-unit CB grafts were 4-6/6 human leukocyte antigen (HLA)-A, -B
antigen, -DRB1 allele matched to the recipient with a cryopreserved total
nucleated cell dose 1.5 107/kg/unit as previously described [20]. Unit-to-
unit HLA match was not considered in unit selection. Units were thawed
with albumin-dextran dilution [21] (n ¼ 58) or were washed (n ¼ 2).
Granulocyte colony-stimulating factor (5 mg/kg/day rounded to vial size)
was given from day 7 until neutrophil recovery.
Study Deﬁnitions
Time to neutrophil recovery was deﬁned as the ﬁrst of 3 consecutive
days with an absolute neutrophil count >.5  109/L. Time to platelet
recovery was deﬁned as the ﬁrst of 3 consecutive days at >50  109/L and at
least 7 days without platelet transfusion support. Sustained donor
engraftment was deﬁned as sustained donor-derived count recovery with
donor chimerism of at least 90% (both units combined). GVHD was diag-
nosed clinically with histologic conﬁrmation when appropriate. Acute and
chronic GVHD were graded according to the International Bone Marrow
Transplant Registry [22] and the National Institutes of Health consensus
criteria [23], respectively.
The primary aim of this study was to obtain a preliminary estimate of
disease-free survival (DFS) at 1 year after CBT. The target sample size was
30 patients. We proposed the treatment would be considered efﬁcacious if
the DFS at 1 year was at least 50%. Using a single-stage design, if at least 19 of
30 patients were disease-free at 1 year, therewould be a 90% conﬁdence that
the true 1-year DFS of >50%. Overall survival and DFS rates were calculated
using Kaplan-Meier methodology, and cumulative incidence was used to
estimate all other outcomes. The permutation log-rank test was used to test
for differences in DFS according to HCT-CI score.
RESULTS
Patient and Graft Characteristics
Table 1 summarizes patient and graft characteristics.
Thirty patients (median age, 56 years) underwent trans-
plantation. Twenty-six had acute leukemia (20 CR1, 5 CR2, 1
CR3), and 4 had MDS. All had high-risk disease (as described
in Table 1), except a single patient who had refractory anemia
with excess blasts e2 that achieved CR after treatment. All
patients had been treated with either chemotherapy (n¼ 28)
or hypomethylating agents (n ¼ 2). Twenty-seven patients
had received therapy within the preceding 3 months, and
3 patients were treated >3 months before transplantation.
The median HCT-CI score [18] was 2.5 (range, 1 to 5). The
age distribution of patients with HCT-CI scores of 1 (n ¼ 11;
median, 55 years; range, 31 to 66), 2 to 3 (n ¼ 9; median,
51 years; range, 35 to 61), and 4 to 5 (n ¼ 10; median,
58 years; range, 18 to 69) was not different (P ¼ .84).
Comorbidities as deﬁned by Sorror et al. [18] included
arrhythmia (n ¼ 1), cardiovascular disease (n ¼ 4), diabetes
(n ¼ 2), depression/anxiety (n ¼ 1), hepatic dysfunction(n ¼ 7, all mild), infection requiring ongoing therapy (n ¼ 5),
pulmonary dysfunction (n ¼ 15, 9 moderate and 6 severe),
and prior solid tumor (n ¼ 4) [13].
Regimen-Related Toxicity, Engraftment, GVHD, and
Infections
The regimen was associated with delayed engraftment
characteristic of myeloablative regimens. Although it was
better tolerated than high-dose chemoradiation, there were
high rates of anorexia, with 21 of 30 patients (70%) requiring
total parenteral nutrition. However, mucositis was not sev-
ere, and only 8 needed patient-controlled analgesia
with narcotics within the ﬁrst 4 weeks posttransplantation.
Three patients suffered organ toxicity, resulting in TRM
as described below. The only late toxicities were associated
with GVHD and its treatment.
Ninety-seven percent (95% conﬁdence interval [CI], 87 to
100) of patients had sustained donor-derived neutrophil
engraftment (Figure 1). The median time to neutrophil
recovery was 26 days (range, 13 to 43). A single, heavily
pretreated patient had graft failure in the context of early-
onset multiorgan failure. The patient’s bone marrow was
100% donor 21 days after transplantation. However, the
patient died 35 days after transplantation without count
recovery. The cumulative incidence of platelet recovery of
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Figure 3. DFS according to the HCT-CI after double-unit CBT using Cy 50/Flu
150/Thio 10/TBI 400 conditioning.
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Figure 1. Cumulative incidence of neutrophil engraftment.
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occurred at amedian of 46 days (range, 30 to 79). Themedian
day 21 total donor bonemarrow chimerismwas 100% (range,
71 to 100) and consisted of 1 unit in 25 of 30 patients (83%).
All surviving patients were 100% donor at 100 days after
transplantation, there were no late graft failures, and sus-
tained hematopoiesis has been mediated by a single unit in
all but 1 patient.
Sixty-seven percent (95% CI, 49 to 84) of patients had
grades II to IV and 7% (95% CI, 0 to 16) had grades III to IV
acute GVHD by day 180 (17 grade II, 2 grade III, and 1 grade
IV). Of the 27 patients who engrafted and were alive at day
100, 3 had chronic GVHD (2 overlap and 1 classical; 2 mild
and 1moderate severity). The 1-year cumulative incidence of
chronic GVHD was 10% (95% CI, 0 to 21).
The pattern of infectious complications was similar to
that previously described in recipients of double-unit CBT
transplanted without ATG [24]. Eighteen of the 21 patients
(86%) who were cytomegalovirus seropositive reactivated
cytomegalovirus at a median of 43 days (range, 14 to 111)0.
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Figure 2. Kaplan-Meier estimate of overall survival and DFS.posttransplantation. However, only 2 had end-organ disease
(both with gastrointestinal involvement, 1 in the setting of
GVHD). Two patients had Epstein-Barr virus viremia
at þ5 and þ 21 months posttransplantation, both in the
setting of treatment for GVHD. Both responded to rituximab
therapy, and no patient had Epstein-Barr virus lymphoma.
TRM, Relapse, and Survival
TRMwas 20% (95% CI, 5 to 35) at day 180 and 28% (95% CI,
11 to 46) at 2 years. Of 8 patients who died of transplant-
related causes, 1 died of graft failure, 4 of GVHD, and 3 of
organ failure (2 pulmonary, 1 central nervous system). No
patient died of infection as the primary cause of death.
Relapse was 11% (95% CI, 3 to 26) at 2 years. With a median
26.5-month (range, 9 to 53) follow-up of survivors, the 2-
year overall survival and DFS were both 60% (95% CI, 44 to
82) (Figure 2).
The comparison of DFS according to pretransplantation
HCT-CI is shown in Figure 3. In the 11 patients (median age,
55 years) with an HCT-CI score of 1, 1 has died of transplant-
related causes and 1 has relapsed, resulting in a 2-year DFS of
82% (95% CI, 62 to 100) in this group. This compares favorably
with the 2-year DFS of 62% (95% CI, 36 to 100) in 9 patients
(median age, 51 years) with a score of 2 to 3 (2 cases of TRM
and 1 relapse), and the 2-year DFS of 40% (95% CI, 44 to 82)
in 10 patients (median age, 58 years) with a score of 4 to 5
(5 cases of TRM and 2 relapses) (permutation log-rank
P ¼ .13).
DISCUSSION
We demonstrate that Cy 50/Flu 150/Thio 10/TBI 400
conditioning supports a high incidence of sustained neu-
trophil and platelet engraftment after double-unit CBT.
This regimen is reduced intensity based on the lower doses
of chemotherapy and TBI than are delivered in high-dose
regimens and as deﬁned by the criteria of Bacigalupo et al.
[25]. However, it remains functionally myeloablative as
illustrated by the delayed neutrophil recovery characteristic
of adult CBT and the median day 21 total donor chimerism of
100%. This is in contrast to the transient autologous recovery
and initial mixed chimerism characteristic of NMA double-
unit CBT [3]. Other centers have investigated CBT with
D.M. Ponce et al. / Biol Blood Marrow Transplant 19 (2013) 799e803802reduced-intensity regimens in an effort to avoid the toxicity
of the most intense regimens. These include melphalan/ﬂu-
darabine [5], melphalan/thiotepa/ﬂudarabine [26], and treo-
sulfan/ﬂudarabine/TBI [27].
The Cy 50/Flu 150/Thio 10/TBI 400 regimen induces
sufﬁcient immunosuppression to facilitate sustained
donor engraftment when combined with a double-unit
CB graft, and this is achieved without the profound
posttransplantation immunosuppression associated with
ATG. It should be acknowledged, however, that our series did
not contain any patient without prior therapy, although 2
patients had received only hypomethylating agents. Patients
without prior combination chemotherapy (who are at an
increased risk of graft rejection after NMA CBT [3]) require
further investigation. Furthermore, although the incidence
rates of both neutrophil and platelet engraftment were high,
the rate of recovery is quite delayed relative to the trans-
plantation of adult donor peripheral blood stem cells. New
strategies, such as a larger CB inventory to enable trans-
plantation of larger and better matched units, ex vivo
expansion [28,29], or the addition of a T celledepleted hap-
loidentical graft [30,31], could further improve the rate of
count recovery after this regimen. In addition, although we
found a high incidence of acute GVHD, most cases were not
severe. Whether the increase in mycophenolate mofetil
dosing will afford more effective GVHD prophylaxis requires
analysis of larger patient numbers. It is likely, however, that
new agents will be needed to augment GVHD prevention
without the disadvantages of ATG. As previously described
by our group, in the absence of ATG, late infection risk was
low in the absence of moderate to severe GVHD [24].
The pretransplantation HCT-CI of Sorror et al. has been
validated as a reliable tool to predict allograft TRM and
survival based on recipient pretransplantation comorbidities
(signiﬁcant prior illnesses and organ dysfunction) [24]. The
utility of the HCT-CI has recently been demonstrated in
a large prospective study [32]. Notably, in our much smaller
double-unit CBT series, an association between HCT-CI and
DFS is also suggested. The low TRM affecting only 1 of 11
patients with a score of 1 is notable, given their relatively
advanced median age of 55 years by CBT standards. Thus, Cy
50/Flu 150/Thio 10/TBI 400 double-unit CBT can be safely
used in patients 50 years old without other major TRM
risks. Although the upper age limit for safe administration of
this regimen is not known, our ﬁndings are highly signiﬁcant
for middle-age patients with high-risk acute leukemias who
are otherwise ﬁt and suggests that double-unit CBT with
Cy 50/Flu 150/Thio 10/TBI 400 could be an immediate alter-
native if an unrelated donor is not identiﬁed within the ﬁrst
few weeks of a search. In contrast, TRM risk for patients with
a high HCT-CI score (4) remains substantial with this
regimen. Unfortunately, high comorbidity scores cannot be
modiﬁed. Although earlier referral of patients with high-risk
disease could reduce the impact of prior therapy, our data
suggest this regimen remains too intense for such patients,
and other treatmentation approaches are needed. These
could include nontransplantation therapies or the investi-
gation of NMA allografts with posttransplantation mainte-
nance to reduce relapse risk as has been investigated for
patients with acute myelogenous leukemia and MDS [33].
Unlike NMA conditioning, which has been associated
with a 31% relapse incidence at 1-year follow-up [8], the
incidence of leukemic relapse in this high-risk population
has been low (11% at 2 years with a median follow-up of
26.5 months). The combined effects of this conditioning andthe graft-versus-leukemia potential of double-unit grafts
[14-17] may well account for this outcome.
It should be acknowledged that this series is relatively
small. Nonetheless, our promising preliminary results
warrant further investigation in patients age 50 years with
high-risk hematologic malignancies, who have high relapse
risks after NMA conditioning and acceptable comorbidity
scores. It may also be a promising alternative to high-dose
conditioning in younger patients with hematologic malig-
nancies, due to the reduced organ toxicity and preservation
of the protection against relapse. As a result, we are now
prioritizing this approach for most of our adult patients
undergoing double-unit CBT, even those previously consid-
ered eligible for high-dose conditioning.ACKNOWLEDGMENTS
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